Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular DystrophyJuly 12, 2018 7:00 AM Pre-Open Movers 07/10: (OCX) (VVUS) (XLRN) Higher; (ISR) (AQXP) (IRBT) Lower (more...)July 10, 2018 9:27 AM Acceleron Pharma (XLRN) PT Raised to $62 at UBSJuly 10, 2018 8:01 AM Acceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results July 10, 2018 7:34 AM Piper Jaffray Downgrades Acceleron Pharma (XLRN) to NeutralJuly 10, 2018 6:31 AM Acceleron (XLRN) option implied volatility flat into Phase III Believe results July 10, 2018 5:24 AM